Journal

Role of Biologics in Chronic Rhinosinusitis With Nasal Polyposis: State of the Art Review

Read time: 1 mins

Published:31st Dec 2020

Author: Kim C, Han J, Wu T, Bachert C, Fokkens W, Hellings P et al.

Source: Otolaryngology–Head and Neck Surgery

Availability: Pay for access, or by subscription

Ref.:Otolaryngol Head Neck Surg. 2021 Jan;164(1):57-66.

DOI:10.1177/0194599820939964

Role of Biologics in Chronic Rhinosinusitis With Nasal Polyposis: State of the Art Review

Objective: To review the current literature regarding the role of biologics in the treatment of chronic rhinosinusitis with nasal polyposis (CRSwNP).

Data sources: PubMed/MEDLINE, EMBASE, Cochrane Review, ClinicalTrials.gov.

Review methods: We conducted a comprehensive review of the literature on clinical studies investigating the efficacy of emerging biologics in CRSwNP, with a focus on randomized controlled trials.

Conclusions: There appears to be promising evidence to support the safety and efficacy of biologics in CRSwNP with and without asthma for select patients. However, additional large-scale randomized studies with longer follow-up are necessary to determine which patients would benefit the most from these novel systemic treatments.

Implications for practice: Chronic rhinosinusitis with nasal polyposis refractory to medical and surgical therapy remains a challenging clinical problem for otolaryngologists. However, emerging biologic therapies may offer a new therapeutic option for such patients with recalcitrant disease.

Read abstract on library site Access full article